Consistent with these findings, a separate study noted the expression of NY-ESO-1 in 16% of TNBC compared with only 2% in ER-positive tumours, and 8 out of 11 (72.7%) patients with NY-ESO-1+ TNBC had measurable antibody responses to NY-ESO-1 [54]. This evidence concerns the gene CTAG1B and neoplasm.